Cytori Therapeutics (CYTX) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of Cytori Therapeutics (NASDAQ:CYTX) from a hold rating to a buy rating in a research report sent to investors on Tuesday, September 4th.

A number of other equities analysts have also issued reports on CYTX. Maxim Group lowered shares of Cytori Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 15th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a hold rating to a buy rating and set a $0.75 target price for the company in a research report on Tuesday, July 31st. Finally, HC Wainwright reiterated a buy rating and issued a $6.00 target price on shares of Cytori Therapeutics in a research report on Wednesday, July 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $10.56.

CYTX opened at $0.50 on Tuesday. Cytori Therapeutics has a 12-month low of $0.31 and a 12-month high of $8.70.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.09). The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $2.50 million. Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. research analysts forecast that Cytori Therapeutics will post -0.85 EPS for the current year.

About Cytori Therapeutics

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

See Also: Exchange-Traded Funds (ETFs)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply